Abivax SA Sponsored ADR (NASDAQ:ABVX) Stock Has Average Target Price of $156.69 According to Brokerages

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned an average rating of “Moderate Buy” from the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, thirteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $155.00.

A number of equities research analysts recently issued reports on ABVX shares. BTIG Research lifted their target price on Abivax from $150.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Citizens Jmp reaffirmed a “market outperform” rating and set a $187.00 price target on shares of Abivax in a research report on Wednesday, July 1st. Guggenheim reaffirmed a “buy” rating and set a $175.00 price target on shares of Abivax in a research report on Tuesday. Leerink Partners raised their price target on shares of Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a report on Thursday, October 15th.

Abivax Trading Down 3.5%

ABVX stock opened at $90.23 on Friday. The stock has a 50-day moving average price of $103.84 and a two-hundred day moving average price of $113.95. Abivax has a 1 year low of $69.81 and a 1 year high of $148.83. The stock has a market cap of $7.90 billion, a PE ratio of -14.89 and a beta of 1.14.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The firm had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million. On average, analysts forecast that Abivax will post -4.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Two Seas Capital LP acquired a new stake in Abivax in the 3rd quarter valued at $66,996,000. Eversept Partners LP lifted its position in Abivax by 42.0% during the 1st quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock worth $104,048,000 after buying an additional 276,589 shares in the last quarter. Bank of America Corp DE lifted its position in Abivax by 40.9% during the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after buying an additional 213,440 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Abivax by 31.6% during the 1st quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after buying an additional 211,068 shares during the last quarter. Finally, Readystate Asset Management LP boosted its stake in shares of Abivax by 111.0% during the 1st quarter. Readystate Asset Management LP now owns 202,022 shares of the company’s stock worth $22,495,000 after buying an additional 106,293 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Company Profile

Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.

Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.